NCI
Neo-Concept International Group Holdings Limited Ordinary Shares
Mentions (24Hr)
0.00% Today
Reddit Posts
Mentions
What do yall think about $NCI for a continatiuon play tomorrow? She hasnt done much in the after hours but she had a good move up right before the 4 p.m bell
NCI halted up again ... tempting
NCI and HTLM setting up some wild Motherland moves. The market is absolutely broken
I love when I try to buy something and fidelity's fuck ass tells me its restricted, and it fucking sends. NCI😔
NCI.V. Pennystock and its value
NCI.V great ratios (P/S less than 1). Very attractive price right now to hold over the next few years
NCI Has good scores, just needs some better price action to apply pressure on the shorts. Peel (recent price gains) and Squeeze Momentum are red today. https://preview.redd.it/dw70ym5itzag1.png?width=764&format=png&auto=webp&s=2ea1f03d7d95df2df3a6a3ee043ec6dcf55b740a
You should check out LRE and NCI
This is not correct. You do not call 49% ownership for non-controlling interest. NCI absolutely does matter and is important to subtract their share of the profits when valuing stocks, as it represents profits that are NOT available to common shareholders.
NCI might be one of my plays today volume is coming in good ..
Trying to find out why NCI is ripping this morning
NCI I mentioned yesterday seems to have went up over night and volume is coming in ..Just watching for now...low float also ..
Hmm NCI low float 800k good volume climbing after hours wondering what the insiders know
You're trying so hard... I'm going to stop sciencing you and let you do your thing. Yours Truly. Clinical Research Nurse Practitioner NIH, NCI
$GNPX Setup looks smarter than people think 🔥 The reverse split and small offering before the AACR presentation were actually well timed. They cleared compliance without tanking the stock. Just enough to reset and give the company room to move. Now all eyes are on today’s data at AACR-NCI-EORTC (Poster Session C) — focused on TUSC2 (REQORSA) in ALK-positive cancers. If the results hit, it’s not just validation… it’s expansion. That’s new market potential and a major credibility boost. Feels like they’ve positioned this perfectly, cleaned up the balance, tightened the float, and now bringing the science front and centre. Could be the start of a real turnaround. #GNPX #REQORSA #GeneTherapy #AACR2025 https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2025/program-saturday-october-25/
Here's chat's take on your take: ✅ Mostly True or Reasonably Grounded 1. PSTV is around $0.50 ✔️ True — The stock is trading in the $0.45–$0.55 range as of late July 2025. 2. FDA-cleared trials are ongoing ✔️ True — The FDA recently cleared an IND for REYOBIQ™ (rhenium nanoliposome therapy) for pediatric brain tumors, and CNSide is being clinically evaluated as a liquid biopsy test. 3. Government support ($17.6M in grants) ✔️ Mostly True — PSTV has received non-dilutive DoD and NIH grant funding, including: $3M+ in recent grants (DoD for REYOBIQ), Previous NIH/NCI awards over $14M (combined over time) Exact total ≈ $17M+, depending on how you count. 4. CNSide is being rolled out in hospitals (e.g. MD Anderson) ✔️ Supported — CNSide has been used in clinical trials involving sites such as MD Anderson and City of Hope. It is not FDA-approved yet, but it's in active trial use. ⚠️ Exaggerated or Speculative Claims 5. “1500% upside” / “Analyst targets $10–$20” ❌ Exaggerated No reputable analyst coverage from firms like Piper, JPM, or B. Riley is currently published on PSTV. The $10–$20 targets appear to be community hype projections, not institutional estimates. A 1500% gain from $0.50 would mean $7.50+, which is not supported by any official forecast. 6. “LIVE product” / “Not hype” 🟡 Partially True CNSide and REYOBIQ are both in clinical use, but neither is FDA-approved or commercially launched yet. These are investigational medical products — not revenue-generating commercial therapies. 7. “No dilution” ❌ Misleading PSTV has a history of raising capital through ATM (at-the-market) equity offerings and private placements. In early 2025, they restructured ~$15M in financing. While grants reduce dilution pressure, the company has and may again raise funds through equity when needed. ❗️ Overall Rating: 3.5 out of 5 (Moderately Truthful) Section Rating Notes Price & trial facts ✅ True Based on real SEC and FDA records Government funding ✅ Mostly True Supported by press releases and grants history Commercial rollout 🟡 Partial Product is not yet FDA-approved or for sale Price targets ❌ Exaggerated No official targets confirm 1000%+ upside Dilution claim ❌ Misleading Company has diluted in past ✅ Final Verdict: The review contains some accurate insights, especially around PSTV’s clinical-stage pipeline, grant funding, and activity in brain cancer. But the price targets and urgency ("this will pop") are speculative hype, not grounded in institutional research or financials. If you’re trading this: Recognize it as a high-risk, speculative biotech, not a guaranteed multi-bagger. Keep position size small and track FDA, 8-K, and trial data closely. Want to follow up with institutional SEC filings or public grant records for PSTV? I can show you exactly where.
7:09 AM EDT, May 06, 2025 (Benzinga Newswire) License Expands Genprex's Portfolio of Oncology Gene Therapy Technologies AUSTIN, Texas, May 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive patent license agreement with UTHealth Houston granting Genprex exclusivity and commercial rights relating to its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for the potential treatment of glioblastoma. The subject patent is co-owned by Genprex and UTHealth Houston, and the license provides Genprex with patent exclusivity. "We are pleased to expand our portfolio of licensed patents and add a technology that uses REQORSA to treat glioblastoma," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. "With this license agreement, Genprex has obtained exclusive commercial rights to REQORSA in glioblastoma while also adding to our patent estate. The role of TUSC2 in lung cancer has been well established, and this latest license enables Genprex to expand the use of REQORSA into a new indication, in which the cancer can be difficult to treat and there are unmet medical needs." REQORSA may be a potential therapeutic treatment for glioblastoma. Genprex previously reported positive preclinical data on the efficacy of REQORSA in glioblastoma in October 2024 at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Research collaborators from UTHealth Houston previously reported TUSC2 as a novel tumor suppressor for glioblastoma, the most common and deadliest primary brain tumor in adults which is associated with a poor prognosis. In their latest study, UTHealth Houston researchers used patient-derived glioblastoma (GBM) cell lines and patient-derived glioma stem cell (PD-GSC) lines. REQORSA was used to restore TUSC2 expression. Write to Benzinga at editorial@benzinga.com
I’m a cancer research her who has watched half my colleagues get furloughed bc the NIH/NCI has been dissolved. That’s not political theater that’s a breaking of a fundamental federal institution that provides a service (academic biomedical research) for the greater good. And you could say the same thing about dep of education, VA hospitals, national park services, the CDC, etc
Its price hit $2+ twice in March. Although I don't know if it'll hit $2 again today but I am optimistic. Here's the news summary (by ChatGPT): The sentiment of this news is **strongly positive**, driven by promising clinical data, high clinical benefit rates, and the absence of significant safety concerns in early trial phases for REYOBIQ™. The tone is optimistic, with credible scientific and regulatory backing (NCI, CPRIT) * New **Phase 1 trial data** for REYOBIQ in Leptomeningeal Metastases (LM) shows **dose-dependent efficacy** and **high clinical benefit**: * Immune response insights from RNA sequencing suggest **apoptosis and immune activation** by Day 28. **Implications:** The data reinforces REYOBIQ’s potential as a **safe, high-dose radiotherapeutic** for a **highly fatal and underserved condition (LM)**. The lack of FDA-approved therapies for LM and the grim prognosis for these patients highlight the **market need** and **clinical urgency**. The tolerability of higher doses without significant toxicity is particularly promising.
NCI is ready for a run.. lots on enthu on stocktwits
NCI and WETH One because it’s the most obvious of pump and dumps and I regret not seeing it. The other just seems to never do anything and I’m stuck with the bag.
MMA.V, NCI.V, and NICU.V show strong growth potential due to strategic partnerships, market positioning, and resource-focused projects.
NYWKF/NCI.V looks solid. They just [landed another $22M three-year contract with 37% margins](https://finance.yahoo.com/news/ntg-clarity-secures-22m-three-120000220.html). Backlog now over $100M. Their Egypt offshore strategy is brilliant - collecting revenue in Saudi Riyal while paying expenses in Egyptian Pounds. Smart move focusing on Saudi Arabia's tech transformation. [Over 180 major companies moved their regional HQs there in first half of 2024](https://finance.yahoo.com/news/ntg-clarity-achieves-109-yoy-033156094.html) including Google and PepsiCo. Perfect timing with Vision 2030 driving massive digital infrastructure spending. 46% insider ownership shows management has skin in the game. Eight straight record quarters. Their strategy of landing long-term contracts instead of one-offs is working. Balance sheet looks way better now too. MGMNF/NICU.V also looking good after that [new copper discovery - 2.3% Cu over 13.9m](https://finance.yahoo.com/news/magna-mining-discovers-copper-zone-120000056.html). Shakespeare project is permitted for 4500tpd operation. Plus that KGHM deal gives them immediate cash flow from McCreedy West. Skip MMA.V for now until we see what that Zambian license actually means for production.
move your $$ north to Chinada - worth %40% moar [NCI.to](http://NCI.to) [VLN.to](http://VLN.to) [PPTA.to](http://PPTA.to) [GSI.to](http://GSI.to) [QTRH.TO](http://QTRH.TO) LUCA.v
TPST WETH NCI RR Please
NCI is going strong; as mentioned yesterday and today we have a PR **HONG KONG, Oct. 22, 2024 (GLOBE NEWSWIRE) --** Neo-Concept International Group Holdings Limited (Nasdaq: NCI) ("the Company") is thrilled to announce the successful completion of its transformative acquisition of the intellectual property (IP) and research and development (R&D) capabilities from its affiliate, Neo-Concept (Holdings) Company Limited ("NCH"). This strategic acquisition empowers NCI with full ownership of the esteemed "Les100Ciels" and "SIU" brands, along with all related trademarks and trade names. Additionally, the transfer includes NCH's talented R&D teams, further enhancing NCI’s potential for innovation. "This is a landmark moment for our company," said Miss Eva Siu, Chairlady and CEO of NCI. "By gaining complete control over our brand assets, we are well-equipped to drive our growth initiative, particularly in the vibrant Middle East market." NCI's Chief Financial Officer, Mr. Patrick Lau, highlighted the financial advantages of this acquisition: "This move not only simplifies our operational structure but also positions us to maximize shareholder returns as we expand our retail footprint across the globe." With the asset transfer now complete, NCI is excited to embark on this new journey, leveraging its enhanced capabilities to deliver innovative products and exceptional experiences to customers worldwide. - END -
I’m buying NCI pre-market. It’s about to make a parabolic move
$NCI is looking primed for a breakout and new HOD. 14.5 million shares have been traded so far and are growing.
Bullish on Gri, NCI, VITAK, TIRX
Waymo is a private company majority owned by Google (or to not confuse you, Alphabet). The portion not owned by Google would be NCI on Google's balance sheet.
anyone in NCI and knows wtf they do?
$NCI why’s no one following👀
Any particular reason why $NCI.V has dropped so much?
$NCI (NTG Clarity Network) is a hidden gem at the moment, in my opinion. Here's a quick DD I sent to my group of my friends not too long ago. I'm usually a lurker here, but the company seems promising. Do your own DD, would love to hear you guys' thoughts. They reported seven consecutive quarters of record-setting revenue growth. In Q2 2024, they posted a revenue of $12.49 million, a 96% increase compared to the same quarter the previous year. *Profitability*: Significant rise in profitability, with a net profit of $2.44 million in Q2 2024, which is a 250% increase from the previous year. This level of profitability is usually pretty rare in the IT services and consulting sector, especially for a company of their size (about ~200 last time I checked) *Positive Balance Sheet*: They absolutely killed it when they improved their financial health by reducing long-term debt and achieved a positive working capital. *Strategic Market Positioning*: Their growth is largely driven by its operations in Saudi Arabia, where demand for digital transformation and IT services is booming due to the country's Vision 2030 plan. They have a long-standing presence in the region, so they are very well positioned to capitalize on these trends.